The first batch of coronavirus vaccine injections nationwide has high hopes for a breakthrough in the fight against COVID-19, but experts are now presenting a more promising possibility: people may only need one injection. , Instead of the current two-dose program.
This prospect will effectively double the available vaccine dose and enable more people to be vaccinated quickly. But this idea sparked a debate. Experts said that there was not enough evidence to justify a single dose and that people should plan to take it twice.
The effort to advance the idea of a single-dose vaccine was recently published by The New York Times. The paper was authored by immunologist Michael Mina and sociologist Zeynep Tufecki of the former Nanchang School of Public Health at Harvard University. Widespread writings are pandemic.
They called for the immediate start of a new clinical trial to study whether a dose of the vaccine is sufficient. They cited data from trials that have been conducted on Pfizer and Moderna vaccines. These data show that the protective effect begins after the first dose of the vaccine, and its effectiveness is as high as 90%, while the effectiveness of the two-dose vaccine is about 95%.
There are questions about how long the protection can last without a second booster dose, but Mina and Tufecki believe that only one dose should be studied immediately.
“If it does, it will change the rules of the game and enable us to vaccinate as many as twice as many people. Not only in the United States but also in countries where vaccine shortages may take years to resolve.”
Part of the problem is that a single use may be less effective than two uses to promote enthusiasm, and each time an average of about 2500 Americans die from the virus, this protection will spread to twice as many people that day, The vaccine is still not widely available in a few months.
“What should we do now so that there will not be 60,000 deaths in one month?” said Christopher Gill, professor of global health at the Boston University School of Public Health. He said that at least there should be a debate on whether to get twice the vaccine immediately for people who get twice the dose without waiting for new trials.
He said: “If you wait, you may be dead.”
Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb questioned the government’s strategy of retaining half the dose to ensure that in the worst case, everyone has enough of the second dose at least Still partly good.
Brett Giroir, Assistant Secretary of the Department of Health and Human Services, stated that the government has already used 2.9 million doses of vaccine as the second dose for 2.9 million people in the first week, rather than deploying all doses immediately.
“We know that the first dose of the drug has a partial protective effect, and there are data currently available, so you want to try to administer as much as possible to benefit as many people as possible,” Gottlieb Pfizer, a current board member, said on CNBC earlier this month .
Other experts, including “Warp Knitting Speed Action” and FDA experts, are evading experts who point out one dose, and point out that this two-dose regimen has been carefully studied for months.
“If the vaccine is approved, the second dose of vaccine will be the entire content of the label,” Moncef Slaoui, chief scientific adviser of the “Warp Speed” operation, said at a press conference. “It strengthens the immunity of patients against COVID-19, which is the data that shows that they have lasting immunity for at least a few months. And I hope it will be very durable. Therefore, people should not use this vaccine as a dose vaccine.”
Nevertheless, he opened the door and continued to learn. “Someone may ask, why not test the efficacy of a dose of a modern vaccine or a Pfizer vaccine?” He added. “This will be a valid question. Of course, timing will be a big challenge.”
Peter Marks, the FDA official in charge of the vaccine review, pointed out in another press conference that the trial and review are based on two doses.
He said: “We spent a lot of time carefully reviewing the data and basing our decisions on science, so that it would be foolish to unknowingly take a single dose,”
Harvard University professor Mina said that the United States should conduct a new trial so that it can know this with certainty, and he said it will take two to three months.
When he talked about a vaccine, he said: “Even if it is slightly inferior from a public health perspective, it may be better.” This means that a less effective vaccine can spread to twice the population, which will have Help reduce the overall spread of the virus faster.
Moderna said that despite this, it has no new trial plan.
“We only studied the two-dose regimen and believe that it is effective for people of different ages and is durable,” a Moderna spokesperson said. “We are not currently planning to study a dosage regimen.”
At the same time, Eric Topol, a professor of molecular medicine at Scripps Research, said that communicating with people is important and they need to take two doses until people know more.
He said on Twitter: “It’s good to study this, but when we really don’t know what protection we can provide, it is disturbing that many people skip the second dose of public information.”
Johnson & Johnson (Johnson & Johnson) is also producing another vaccine, which may have results in the third phase of trials early next year. The vaccine is used only once.